Canada Eyes Reducing Reliance On Pricing As Sole Reward for Innovation
A New Framework For Funding Rare Disease Treatments Is Under Consideration
Executive Summary
Up-front R&D investments from third parties in an effort to share risk and reduce industry’s reliance on pricing as the sole reward for innovation could be on the cards in Canada, as could a new single approach for deciding which drugs to cover.